Drug Watch: Agents in late-stage development for the treatment of ophthalmic disorders (February 2006) (PDF)

News
Article

A review of agents in late-stage development for the treatment of ophthalmic disorders (January 2006)

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
Related Content
FDA Approves Eydenzelt, Additional Eylea Biosimilar

FDA Approves Eydenzelt, Additional Eylea Biosimilar

Logan Lutton
October 11th 2025
Article

Read More

Repatha Now Available for Approximately 60% Off List Price

Repatha Now Available for Approximately 60% Off List Price

Logan Lutton
October 11th 2025
Article

Read More

Taljat-stock@abode.com

Novartis to Offer Cosentyx to Cash Paying Patients at a 55% Discount

Denise Myshko
October 11th 2025
Article

Read More

Novo Nordisk Resubmits BLA for Once-Weekly Insulin for Type 2 Diabetes

Novo Nordisk Resubmits BLA for Once-Weekly Insulin for Type 2 Diabetes

Denise Myshko
October 11th 2025
Article

Read More

FDA Approves Extended Indication for Evkeeza

FDA Approves Extended Indication for Evkeeza

Logan Lutton
October 11th 2025
Article

Read More

Valeriya Zankovych-stock@adobe.com

AstraZeneca to Offer Airsupra Direct to Patient

Denise Myshko
October 11th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.